세계의 공격적 섬유종증 시장 : 치료 유형, 유통 채널, 최종 사용자별 예측(2025-2030년)

The Aggressive Fibromatosis Market was valued at USD 2.74 billion in 2023, expected to reach USD 2.90 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 4.10 billion by 2030.

Aggressive fibromatosis, also known as desmoid tumors, is a rare type of locally invasive tumor which arises from the musculo-aponeurotic structures and does not metastasize. The market scope for aggressive fibromatosis primarily revolves around the development, application, and commercialization of effective therapies, emphasizing surgical interventions, pharmacological treatments, and advanced therapeutic approaches such as targeted therapy and immunotherapy. This condition notoriously poses a clinical challenge given its recurrence post-surgery and limited effective pharmacotherapy. The necessity for novel treatment regimens can be particularly attributed to the need to prevent recurrence and manage morbidity without excessive adverse effects. The end-use scope primarily targets hospitals, specialty clinics, and cancer treatment centers where patients seek diagnosis and treatment. Key growth drivers in this market include heightened awareness about the condition, advancements in diagnostic imaging techniques, and the increasing interest in research and development for more effective therapeutic methods. Potential opportunities lie in developing non-invasive therapies, expanding into emerging markets with unmet medical needs, and leveraging biotechnology for innovative drug delivery systems. Nonetheless, the market faces limitations such as high treatment costs, the rarity of the condition which may limit market size, and regulatory hurdles which pose challenges to new market entrants. Funding constraints for research into rare diseases further impact growth prospects. For innovation and business growth, targeted research in molecular genetics, robust clinical trials for novel drug formulations, and collaborations for knowledge sharing among global institutions offer viable pathways. The market is largely niche but poised for growth driven by technological advances in oncology research and a strategic focus on orphan drug development. In essence, substantial investment in research, coupled with a strategic focus on education and patient advocacy, could significantly enhance market dynamics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Aggressive Fibromatosis Market

The Aggressive Fibromatosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising awareness among healthcare providers and more accurate diagnosis of aggressive fibromatosis
  • Regulatory support and orphan drug designations encouraging the development of treatments for rare diseases
  • Growing collaboration and partnerships between pharmaceutical companies, research institutions, and academic centers to accelerate the development of new treatments
• Market Restraints
  • High R&D Costs required to develop and bring new therapies to market particularly for niche conditions
• Market Opportunities
  • Advances in medical research and technology of the genetic and molecular basis of aggressive fibromatosis
  • Integration in digital health technologies such as telemedicine, mobile health apps, and wearable devices for monitoring treatment response and patient adherence
• Market Challenges
  • Limited treatment options and targeted therapies for aggressive fibromatosis

Porter's Five Forces: A Strategic Tool for Navigating the Aggressive Fibromatosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Aggressive Fibromatosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Aggressive Fibromatosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Aggressive Fibromatosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Aggressive Fibromatosis Market

A detailed market share analysis in the Aggressive Fibromatosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Aggressive Fibromatosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Aggressive Fibromatosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Aggressive Fibromatosis Market

A strategic analysis of the Aggressive Fibromatosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Aggressive Fibromatosis Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, AbbVie Inc., Amgen Inc., AstraZeneca plc, Aurinia Pharmaceuticals Inc., Bayer AG, Bioporto Diagnostics A/S, Boston Scientific Corporation, Celgene Corporation (a Bristol-Myers Squibb Company), Eli Lilly and Company, Epizyme, Inc., Exelixis, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Infinity Pharmaceuticals, Inc., Johnson & Johnson Service, Inc., Medtronic plc, Merck & Co., Inc., Novartis AG, Oncoheroes Biosciences Inc., Pfizer Inc., Sanofi S.A., SpringWorks Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Aggressive Fibromatosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Non-Surgical Treatment and Surgical Treatment. The Non-Surgical Treatment is further studied across Cryoablation, Pharmacological Therapies, Radiation Therapy, and Radiofrequency Ablation. The Surgical Treatment is further studied across Conservative surgery and Radical resection.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, Research & Academic Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising awareness among healthcare providers and more accurate diagnosis of aggressive fibromatosis
    • 5.1.1.2. Regulatory support and orphan drug designations encouraging the development of treatments for rare diseases
    • 5.1.1.3. Growing collaboration and partnerships between pharmaceutical companies, research institutions, and academic centers to accelerate the development of new treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High R&D Costs required to develop and bring new therapies to market particularly for niche conditions
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in medical research and technology of the genetic and molecular basis of aggressive fibromatosis
    • 5.1.3.2. Integration in digital health technologies such as telemedicine, mobile health apps, and wearable devices for monitoring treatment response and patient adherence
  • 5.1.4. Challenges
    • 5.1.4.1. Limited treatment options and targeted therapies for aggressive fibromatosis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Growing preference for non-surgical treatments owing to their minimally invasive nature
  • 5.2.2. End User: Increasing need for ambulatory surgical centers offering minimally invasive surgical interventions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Aggressive Fibromatosis Market, by Treatment Type

• 6.1. Introduction
• 6.2. Non-Surgical Treatment
  • 6.2.1. Cryoablation
  • 6.2.2. Pharmacological Therapies
  • 6.2.3. Radiation Therapy
  • 6.2.4. Radiofrequency Ablation
• 6.3. Surgical Treatment
  • 6.3.1. Conservative surgery
  • 6.3.2. Radical resection

7. Aggressive Fibromatosis Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Pharmacies
• 7.4. Retail Pharmacies

8. Aggressive Fibromatosis Market, by End User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals
• 8.4. Research & Academic Institutes
• 8.5. Specialty Clinics

9. Americas Aggressive Fibromatosis Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Aggressive Fibromatosis Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Aggressive Fibromatosis Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. European Medicines Agency validates SpringWorks Therapeutics' application for nirogacestat, a groundbreaking treatment for desmoid tumors, following phase 3 DeFi trial results
  • 12.3.2. SpringWorks Therapeutics' nirogacestat MAA accepted by EMA, paving the way for first EU-approved therapy for desmoid tumors, showcasing significant clinical benefits from Phase 3 trial outcomes
  • 12.3.3. Immunome acquires Phase 3 gamma secretase inhibitor AL102 from Ayala for $50M to enhance cancer therapy portfolio and clinical outcomes
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4D Molecular Therapeutics
• 2. AbbVie Inc.
• 3. Amgen Inc.
• 4. AstraZeneca plc
• 5. Aurinia Pharmaceuticals Inc.
• 6. Bayer AG
• 7. Bioporto Diagnostics A/S
• 8. Boston Scientific Corporation
• 9. Celgene Corporation (a Bristol-Myers Squibb Company)
• 10. Eli Lilly and Company
• 11. Epizyme, Inc.
• 12. Exelixis, Inc.
• 13. GlaxoSmithKline plc
• 14. Hoffmann-La Roche Ltd.
• 15. Infinity Pharmaceuticals, Inc.
• 16. Johnson & Johnson Service, Inc.
• 17. Medtronic plc
• 18. Merck & Co., Inc.
• 19. Novartis AG
• 20. Oncoheroes Biosciences Inc.
• 21. Pfizer Inc.
• 22. Sanofi S.A.
• 23. SpringWorks Therapeutics, Inc.
• 24. Takeda Pharmaceutical Company Limited
• 25. Teva Pharmaceutical Industries Ltd.